FDA Ad Com next month for Mesoblast’s remestemcel-L for graft-v-host disease

The FDA’s Oncologic Drugs Advisory Committee will meet on Thursday, August 13, to review and discuss Mesoblast Limited’s (MESO +5.9%) marketing application for Ryoncil (remestemcel-L) for the treatment of children with steroid-refractory acute graft versus host disease (GvHD).

Under Priority Review status, the agency’s action date is September 30.

Ryoncil is an allogeneic mesenchymal stem cell product derived from bone marrow.

https://seekingalpha.com/news/3593097-fda-ad-com-next-month-for-mesoblasts-remestemcel-l-for-gvhd